Pipette dropping stem cell research fluid on pcr plate. Medical
Pipette dropping stem cell research fluid on pcr plate. Medical
Pipette dropping stem cell research fluid on pcr plate. Medical

LIFE SCIENCES

The health and well-being sectors are of vital importance and continue to evolve. Advances in nanotechnology, genetic mapping and medical devices are opening up new opportunities for industry players, while improving peoples’ lives around the world. McMillan’s life sciences lawyers represent clients in both the private and public sector in the biotechnology, pharmaceuticals and healthcare industries. We understand the challenges and opportunities that life science law presents.

As a top healthcare and life sciences law firm, McMillan LLP employs strategic legal counsel to help our clients meet the industry’s challenges head-on while positioning them to profitably bring innovations to the market. With our integrated approach, we can deliver comprehensive, customized legal solutions in the most challenging circumstances.

HEALTHCARE

Public institutions and private enterprises operating in the complex healthcare sector require the services of healthcare lawyers who understand both the challenges and opportunities of the industry.

By combining a passion for healthcare and significant industry experience, McMillan lawyers provide clients with practical and relevant legal advice. We work with North America’s leading hospitals, managed care companies, clinics and laboratories, as well as investors, insurers, lenders and venture capital involved in the industry.

Among the ways McMillan works with clients are through advising on the latest healthcare legislation, reimbursement regulations, and director and officer obligations; representing healthcare professionals in disciplinary matters; negotiating service contracts with third-party providers, facilities and joint ventures; advising on mergers, acquisitions and divestitures; representing healthcare professionals in dispute resolution and litigation, including class actions; and advising on tax and privacy matters

PHARMACEUTICALS

The pharmaceutical industry combines the business and science of the healthcare sector. Drugs can take many years and millions of dollars in research and development costs to bring to market. Though challenging, pharmaceutical development is also rewarding. McMillan lawyers understand the process of developing, testing and marketing pharmaceutical products. We combine a thorough knowledge of healthcare laws and regulations with a passion for helping clients bring life-saving and life-enhancing drugs to market.

McMillan’s life sciences industry lawyers work with clients to advise on patent and trademark matters; represent them in intellectual property litigation; assist with mergers, acquisitions and divestiture; structure financing arrangements through private equity, public markets and venture capital; advise on drug pricing and reimbursement strategies; assist with regulatory approvals; draft clinical trial, licensing and collaboration, and supply, manufacturing and distribution agreements; advise on labelling, advertising and distribution matters; represent them in product liability litigation and class actions; and advise on tax matters.

BIOTECHNOLOGY

Biotechnology is a complex business that faces many challenges to bring their products to market profitably. Government regulation, intellectual property issues and securing financing all require expert Biotech lawyers and expert industry awareness.

At McMillan, our lawyers combine strong industry expertise in Biotech law with vital knowledge of the legal and regulatory environments that impact the industry. By using a multidisciplinary approach, we provide Biotech companies with effective solutions so that they can continue to develop life-saving and life-enhancing advances.

Among the ways McMillan lawyers assist biotech clients is with intellectual property issues, such as patents, trademarks, licensing, outsourcing and strategic alliances; advising on regulatory issues concerning sales and marketing, pricing, privacy, research and development processes, competition and trade; structuring public and private corporate finance, mergers, acquisitions and divestitures; negotiating government contracts; representing them in litigation proceedings related to product liability, commercial disputes, consumer class actions and intellectual property; and advising on research tax incentives.

Primary Contacts

View All Contacts

News

Insights (10 Posts)View More

Featured Insight

The Pause on the Tariff War: How Businesses Can Use the Reprieve Wisely

Canadian businesses should prepare for US tariffs, set for March 4, 2025, by considering availability of duty drawbacks and remission applications.

Read More
Feb 5, 2025
Featured Insight

Patent Term Adjustments in Canada Are Here

On January 1, 2025, provisions related to Canada’s new patent term adjustment framework came into force. This bulletin provides an overview of these changes.

Read More
Jan 20, 2025
Featured Insight

Exploring the No-Go Zones: Overview of the Guidance Issued by the Canadian Privacy Regulator Relating to Inappropriate Purposes

In this bulletin, we provide an overview of "No-Go Zones" identified by the OPC, including emerging No-Go Zones.

Read More
Dec 17, 2024
Featured Insight

Plan Ahead: CIPO’s Adjustments to Its Fees Come Into Effect on January 1, 2025

CIPO government fees will increase in 2025. Where possible, applicants and registrants may wish to take action before the 2025 fees come into effect.

Read More
Nov 26, 2024
Featured Insight

Towards a Shared Understanding: Canada’s New Sustainable Investment Guidelines & Mandated Climate Disclosures

Canada’s New Sustainable Investment Guidelines (Taxonomy) & Mandated Climate Disclosures

Read More
Nov 4, 2024
Featured Insight

Quebec’s Anonymization Regulation: A Step-by-Step Guide For Businesses

In this bulletin, we provide you a step-by-step guide to understanding the Quebec anonymization regulation.

Read More
Sep 9, 2024
Featured Insight

Understanding Privacy Policies: Clarifying What They Are Not, and Avoiding Common Misconceptions

In this bulletin, we explain what a privacy policy is by looking at what it is not.

Read More
Aug 21, 2024
Featured Insight

Overview of the Canadian Legal Framework Relative to Artificial Intelligence Systems Following the Adoption of the AI Act in Europe

This article provides you with an overview of the Canadian legal landscape relative to AI systems following the adoption of the AI Act in Europe.

Read More
Aug 9, 2024